Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors

Inclusion Criteria: * Patients with a cytopathologically or histopathologically confirmed diagnosis of an advanced solid tumor, excluding breast cancer which has progressed despite standard therapy or for which no standard therapy exists * ECOG performance status 0 or 1 and anticipated life expectancy ≥ 3 months * Patient must meet protocol-specific laboratory values Exclusion Criteria: * Patients with brain metastases * Patients who have received or who are expected to receive any prohibited medications and therapies * Patients who have received CYP1A2 inducer, CYP2C9/2C19 inducer or CYP3A4 inducer medications within 30 days prior to start study treatment or are expected to receive during the first 14 days after starting the study treatment * Patients with a known hypersensitivity to benzodiazepines * Patients who have not recovered from previous anti-cancer therapies * Patient with impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of TKI258 * Patients who have concurrent severe and/or uncontrolled concomitant medical conditions that could compromise participation in the study * Female patients who are pregnant or breast-feeding * Fertile males or women not willing to use highly effective methods of contraception * Other protocol-defined inclusion/exclusion criteria will apply